Patent intelligence · CA
CA 2859273
POLYMERES CATIONIQUES A BASE DE GLYCOGENE
POLYMERES CATIONIQUES A BASE DE GLYCOGENE
Patent details — CA 2859273
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Sep 19, 2013
- Expiration
- Sep 14, 2033
- Applicant
- ACRAF [IT]
- CPC classes
- A61K 47/ 48 A I, A61K/31713, A61K/31716, A61K/4750
Quick answer
CA 2859273 (POLYMERES CATIONIQUES A BASE DE GLYCOGENE) is held by ACRAF [IT]. Status: granted. Granted Sep 19, 2013. Expires Sep 14, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ACRAF [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 47/ 48 A I, A61K/31713, A61K/31716, A61K/4750, A61K/4761
More from ACRAF [IT]
Related pharmaceutical patents in our USPTO index.
-
EP 3807294
PEPTIDE MIT HEMMENDER WIRKUNG AUF MUSKARINREZEPTOR M3
granted -
EP 3807293
PEPTIDE MIT HEMMENDER WIRKUNG AUF NEURONALE EXOZYTOSE
granted -
CA 3135097
COMBINAISON PHARMACEUTIQUE COMPRENANT DE LA TRAZODONE POUR LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
granted -
WO 2020178316
AZAINDAZOLES EN 5 OU 7 UTILISÉS COMME INHIBITEURS DE BÊTA-LACTAMASE
granted -
WO 2020074463
COMPOSITION LIQUIDE ORALE COMPRENANT DU TRIPTAN
granted -
CA 3094896
COMPOSES DE 1H-INDAZOLE-3-CARBOXAMIDE UTILISES EN TANT QU'INHIBITEURS DE LA GLYCOGENE SYNTHASE KINASE 3 BETA
granted -
CA 3089552
PROCEDE CONTINU DE PREPARATION DE TRAZODONE
granted -
CA 3079530
COMPOSITION LIQUIDE STABLE DE KETOPROFENE, SELS ET ENANTIOMERES DE CELUI-CI
granted
Frequently asked questions
What is US patent 2859273?
CA 2859273 (POLYMERES CATIONIQUES A BASE DE GLYCOGENE) is held by ACRAF [IT]. Status: granted. Granted Sep 19, 2013. Expires Sep 14, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2859273?
ACRAF [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 2859273 expire?
Our index shows an expiration date of Sep 14, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.